LONDON, Dec. 12, 2024 /PRNewswire/ — MYCOM OSI, a leading independent provider of Network Assurance and Service Experience Assurance solutions to some of the world’s largest communications service providers (CSPs), today announced that it has been selected alongside Globe, one of the…
Tag: PR Newswire
MADRID, Dec. 12, 2024 /PRNewswire/ — Equiduct, the retail-focused pan-European exchange, announced today that iBroker Global Markets S.V. is the newest trading participant to join its Best Execution service, Apex. iBroker is the leading online broker in listed derivatives in Spain,…
MADRID, Dec. 12, 2024 /PRNewswire/ — Equiduct, the retail-focused pan-European exchange, announced today that iBroker Global Markets S.V. is the newest trading participant to join its Best Execution service, Apex. iBroker is the leading online broker in listed derivatives in Spain,…
MADRID, Dec. 12, 2024 /PRNewswire/ — Equiduct, the retail-focused pan-European exchange, announced today that iBroker Global Markets S.V. is the newest trading participant to join its Best Execution service, Apex. iBroker is the leading online broker in listed derivatives in Spain,…
MADRID, Dec. 12, 2024 /PRNewswire/ — Equiduct, the retail-focused pan-European exchange, announced today that iBroker Global Markets S.V. is the newest trading participant to join its Best Execution service, Apex. iBroker is the leading online broker in listed derivatives in Spain,…
Paving a Design and Innovation-Driven Path Forward to a Sustainable Future with France Italy announced as Partner Country for BODW 2025 HONG KONG, Dec. 12, 2024 /PRNewswire/ — The Business of Design Week 2024 (BODW 2024), Asia’s premier international annual event on design, innovation…
Paving a Design and Innovation-Driven Path Forward to a Sustainable Future with France Italy announced as Partner Country for BODW 2025 HONG KONG, Dec. 12, 2024 /PRNewswire/ — The Business of Design Week 2024 (BODW 2024), Asia’s premier international annual event on design, innovation…
SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored…
SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored…
New therapies will allow patients greater choice and flexibility in the control of CNS disorders BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, Dec. 12, 2024 /PRNewswire/ — Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the…
